gms | German Medical Science

104th DOG Annual Meeting

21. - 24.09.2006, Berlin

Retina laser coagulation as major treatment of diabetic retinopathy patients

Meeting Abstract

Search Medline for

  • T. A. Birich - Belorussian State Medical University, Minsk, Belarus
  • T. V. Morchat - Belorussian State Medical University, Minsk, Belarus

Deutsche Ophthalmologische Gesellschaft e.V.. 104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft (DOG). Berlin, 21.-24.09.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06dogP146

The electronic version of this article is the complete one and can be found online at:

Published: September 18, 2006

© 2006 Birich et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.




Laser coagulation (LC) is used to discontinue functioning of neulyformed vessels presenting major cause of developing heavy irreversible transformation of he organ of sight, haemophtalm, tractional detachment of retina, etc. (J. C. Javitt, J. C. Conner, R. G. Frank et al, 1990). The opinion the WHO research group is that early diagnosis and treatment of diabetic retinopathy (DR) by laser coagulation terminates its development, preserving sight in some 70 per cent of cases (Veselovskaua Z.F., Saluta M. E., 2000, J.C. Javitt et al., 1991, Kohner E.M., Porta M., 1992). The objective of the investigation was to analyses laser coagulation treatment of the patients with DR.

Materials and methods

LC of 51 cases (102 eyes): 31 cases of the first type, 20 cases of the second type of DR and maculopathy were analysed. Alongside with general clinical and special methods of examination, the eye bottom of all the patients was electrophotoed. Focal LC was practiced on 21 patients (42eyes), panretinal LC in 19 patients (38 eyes), combination of both – on 11 patients (22 eyes). The patients were controlled after LC from 3 months up to 2 years. Control examination were in 3-4 weeks after focal LC due to macula oedema, and in 3 months after panretinal LC. Remote control examinations of the 51 patients were also performed. Special attention was paid to patients with DR of 20-31 and 41-45 grades (after Wisconsin). Particularly in these groups there exists much probability of developing macula oedema that requires urgent LC to prevent transformation of non-proliferative retinopathy into proliferative one endangering the sight. The second group of diabetic patients at the stage of 51-55 and over 61 grand (patients with preproliferative and proliferative retinopathy). Our analysis shows that LC treatment at an stage resulted in gaining good eyesight (0.5-1.0) (70 eyes - 68.8%) with most of the patients. Weak eyesight (0,1) had 6 eyes (5.8%) in cases of initial proliferative changes at the eye bottom: 2 patients of the 51-55 grade, more than 61 - 3 patients. 54 eyes (53%) had 0.7-1.0 eyesight. Our control of LC treated patients testified to stabilization of visual functions and the eye bottom with most patients (96.1%).


Early diagnosis of initial vascular pathology and of retina tissue with diabetic patients is important for subsequent monitoring the cases and early LC treatment. The results obtained testify that LC treatment of SD and DR patients stabilizes the state of the eye bottom and eyesight in 96.1% of eyes a remote stages of control.